Business
Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination
Study intended to evaluate safety, and potential immunomodulatory effect of Lomecel-B on aging-associated decline in antibody response to vaccines in
About this update from Longeveron Inc.
[{"type":"text","content":"Study intended to evaluate safety, and potential immunomodulatory effect of Lomecel-B on aging-associated decline in antibody response to vaccines in vulnerable population. Trial funded in part by a grant from Maryland Technology Development Corporation (TEDCO) and the National Institute on Aging (NIA) of the National Institutes of Health (NIH) Top-line data expected in Q3 2021 MIAMI, April 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (\"Longeveron\" or \"Company\"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the completion of the Company’s Phase I/II clinical study of the use of Lomecel-B to improve immune response to influenza (“flu”) vaccine in subjects with Aging Frailty. Lomecel-B is an allogeneic, bone marrow-derived medicinal signaling cell (MSC) product manufactured under current good manufacturing practices (cGMP) by Longeveron. The two-phase, multicenter, randomized, double-blinded, placebo-controlled study was conducted at 7 hospitals and clinics throughout Florida and Maryland, and was supported in part by a grant from Maryland Stem Cell Research Fund (MSCRF) under the Maryland Technology Development Corporation (TEDCO) and the National Institute on Aging (NIA). It is well established that an aging immune system is less effective at producing protective antibodies following vaccination, and this reduced immune response contributes to the aging process in general (referred to as “inflammaging” by geriatricians). People with aging frailty are more prone to inflammaging and are more likely to have greater susceptibility to infectious diseases and reduced responses to vaccination. Although commercially available vaccines against influenza provide protection and likely lasting immunological memory in children and adults, they are much less effective in older and frail individuals. Lomecel-B has the potential to reduce inflammation associated with Aging Frailty, and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can balance the immune system and improve the function of B lymphocytes. As B cells are responsible for antibody production in response to vaccines, Lomecel-B may boost antibody generation and immunity following vaccination in subjects with Aging Frailty. It is ...